Viridos

Synthetic Genomics, Inc. specializes in developing innovative biofuels from engineered microalgae, addressing the urgent need for sustainable energy solutions across various sectors, including aviation and shipping. Founded in 2005 in the United States, Synthetic Genomics, Inc. focuses on creating low-carbon intensity biofuels.

The company has raised a total of USD 25. 00 mn in funding, with its most recent Series A round occurring on March 13, 2023, led by Breakthrough Energy Ventures alongside Chevron Corporation and United Airlines Ventures. The current CEO is Oliver Fetzer. Viridos specializes in the development of low-carbon intensity biofuels derived from engineered microalgae, addressing critical challenges in decarbonizing industries such as aviation, commercial trucking, and maritime shipping.

Their core offerings include proprietary algal strains optimized for high oil production, capable of flourishing in saltwater and climate conditions that do not compete with agricultural resources. The company operates various production sites where these microalgae are cultivated sustainably. Viridos targets markets globally, particularly focusing on North America and regions requiring renewable fuel alternatives to fossil fuels. Their innovative approach not only enhances biofuel yield but also integrates ecological sustainability, positioning them as a key player in the renewable energy sector.

The revenue structure of Viridos is derived from collaborations and partnerships within the biofuel industry, particularly with clients in heavy transportation sectors. These transactions typically occur through B2B arrangements where Viridos supplies its advanced algal biofuels to commercial entities such as airlines, freight companies, and shipping firms. By offering high-quality, sustainable fuel alternatives, the company bolsters its client relationships and facilitates long-term contracts. Specific pricing models reflect a commitment to competitive rates in the renewable energy market, with financial arrangements structured around volume commitments and supply agreements.

The flagship offerings of Viridos, including their lead engineered algal strains and technologies for algal oil extraction, serve as the cornerstone for their revenue generation strategy. With the recent funding of USD 25. 00 mn raised in March 2023, Viridos plans to further develop its research in algae oil for market production. The company aims to expand its product offerings and enhance its market presence, particularly in North America and other regions seeking renewable fuel alternatives.

This strategic funding will support advancements in their algal strains and cultivation technologies, positioning them for future growth in the biofuels sector.